Healthcare
Live Price
Offline$0.7405
+0.00% today
1Y Change
+32.26%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Top Glove Corporation Bhd. (TGLVY) is a Healthcare stock with a market cap of $5.77B and listed on OTC. The stock last traded around $0.74 and up 32.3% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +38.8%, EPS growth of +267.9%, a dividend yield of 0.7%. What stands out right now is revenue +38.8%, EPS +267.9%, free cash flow +227.6% with operating margin 3.7% and ROIC 2.0%. The dividend is present but secondary, with a yield around 0.7%. Valuation already assumes a fairly strong business story at P/E 40.5 and price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TGLVY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TGLVY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TGLVY Max Drawdown
-36.27%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TGLVY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$16.4B
+193.6% YoY
FY Net Income
$7.8B
+2715.0% YoY
Free Cash Flow
$6.5B
+937.9% YoY
Revenue Growth
+38.8%
EPS Growth
+267.9%
Gross Margin
26.5%
Net Margin
4.0%
Income statement
MYR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.5B | 2.5B | 2.3B | 5.6B | 16.4B |
| Gross Profit | 89M | 265M | 64M | 953M | 11.1B |
| Operating Income | 89M | -183M | -533M | 355M | 10.0B |
| EBITDA | 456M | 266M | -545M | 711M | 10.3B |
| Net Income | 132M | -18M | -879M | 276M | 7.8B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
MYR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 298M | 283M | 280M | 433M | 875M |
| Total Assets | 6.3B | 7.0B | 7.1B | 8.1B | 9.8B |
| Total Liabilities | 1.5B | 1.1B | 1.1B | 1.3B | 2.6B |
| Shareholder Equity | 4.8B | 5.8B | 5.9B | 6.8B | 7.2B |
| Total Debt | 850M | 422M | 582M | 417M | 482M |
| Net Debt | 551M | 139M | 302M | -16M | -393M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7.8B
+4277.2% YoY
Capital Expenditures
1.3B
-40.0% YoY
Free Cash Flow
6.5B
+937.9% YoY
Key ratios
Gross Margin
26.5%
Operating Margin
3.7%
Net Margin
4.0%
ROE
3.0%
Debt / Equity
0.18x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.